Fig. 5.1
Multicolor flow cytometric immunophenotyping on fine-needle aspiration sample (example 1): the histogram shows coexpression of CD19 and CD5, an important feature of mantle cell lymphoma
Fig. 5.2
Multicolor flow cytometric immunophenotyping on fine-needle aspiration sample (example 2): the histogram shows monotypic B-cell population with lambda light chain restriction
In nonneoplastic conditions, the specimen comprises a mixture of T and B cells. In addition to CD19, CD20, and CD22, mature nonneoplastic B cells typically express polytypic surface immunoglobulin. B-cell lymphomas, however, express a single clonal light chain (also called light chain restriction ), so the kappa-to-lambda ratio is either substantially increased or decreased due to a significant lambda excess. Ki67 immunostaining on cytospin preparation (Fig. 4.13) is often included in lymphoma workup to help tumor grading, to aid in the diagnosis of Burkitt lymphoma , or to confirm the blastoid nature of mantle cell lymphoma. The aberrant expression of some antigens in B-cell lymphomas may be of prognostic value. For example, CD38 expression in B-cell SLL/CLL is often associated with a more aggressive clinical course. Table 5.1 lists the key immunophenotypic and molecular features of mature B-cell neoplasms commonly encountered in cytology practice.
Table 5.1
Immunophenotypic and molecular features of mature B-cell neoplasms commonly encountered in cytology practice
Tumor type | Immunophenotype | Cytogenetic change |
---|---|---|
Burkitt/atypical Burkitt lymphoma | CD45+, sIg+, CD79a+, CD19+, CD20+, CD10+, BCL6+, high Ki67 index (nearly 100 %) | Most common: t(8;14)(q24;q32); less common: t(2;8)(p12;q24) or t(8;22)(q24;q11) |
CD5−, CD23− | ||
Follicular lymphoma | CD45+, sIg+, CD79a+, CD19+, CD20+, CD10+ (occasionally CD10−), BCL6+ | Most common: t(14;18)(q32;q21); rarely: t(2;8)(p11;q21) and t(18;22)(q21;q11) |
CD5−, CD23+/− | ||
Large B-cell lymphoma | CD45+, sIg+, cIg+ or Ig undetectable, CD79a+, CD19+, CD20+, high Ki67 index | t(14;18)(q32;q21) |
CD10−/+, BCL6−/+, CD5−/+ | ||
Lymphoplasmacytic lymphoma | CD45+, sIg+, cIg+, CD79a+, CD19+/−, CD20+/−, CD38+, CD43+/− | |
CD10−, CD5−, CD23− | ||
Mantle cell lymphoma | CD45+, sIg+, CD79a+, CD19+, CD20+, CD5+, FMC7+, CD79a+, BCL1 (cyclin D1)+, SOX11+ | t(11;14)(q13;q32) |
CD10−, CD23− | ||
Marginal zone lymphoma (splenic or nodal) and MALT lymphoma | CD45+, sIg+, CD79a+, CD19+, CD20+ | t(11,18)(q21;q21), t(14;18)(q32;q21), t(3;14)(p14.1;q32), trisomy 3, and trisomy 18 (more common in MALT lymphoma) |
CD10−, CD5−, CD23−, BCL6− | ||
Plasma cell neoplasms | CD45+/−, cIg+, CD79a+, CD38+, CD138+, MUM1+, CD56+/− | t(11;14)(q13;q32) |
CD19−, CD20−, sIg− | ||
Small lymphocytic lymphoma/chronic lymphocytic leukemia | CD45+, dim sIg+, CD79a+, CD19+/−, dim CD20+, dim CD22+, CD5+, CD23+, (CD38+, and ZAP70+: worse prognosis) | Trisomy 12, 13q14 deletion, 17p and 11q deletions |
CD10−, FMC7− |
Although in most cases, the interpretation of flow cytometric data is quite straightforward, traps may be encountered. Correlation of flow cytometric data with clinical and cytologic findings and Ki67 staining is important. In rare cases, cytogenetic or molecular studies may also be needed. Interpreting a case solely on the basis of flow cytometric results may lead to an erroneous diagnosis. Negative findings do not necessarily indicate a benign process.
Immunoglobulin light chain restriction may not be detectable due to too few neoplastic cells, which may be masked by abundant benign lymphocytes, a situation often seen in T-cell-rich large B-cell lymphoma or a partially involved node. Gating on the large cell population may separate neoplastic large cells from the reactive lymphocytes. In the case of partial involvement by follicular lymphoma, typically CD10-positive B cells demonstrate light chain restriction, whereas CD10-negative B cells express polyclonal light chain consistent with a nonneoplastic nature. In difficult cases, immunoglobulin heavy-chain (IgH) rearrangement can be detected using molecular study (see Chap. 7).Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree